Replies to post #186847 on Biotech Values

[DewDiligence]

We’re seeing some decidedly low-quality IPOs recently.

[DewDiligence]

(TCON)—Santen files IND for DE-122 in wet AMD:

http://finance.yahoo.com/news/tracon-pharmaceuticals-announces-ind-filing-110000163.html

DE-122 is the ophthalmic formulation of TRACON's proprietary anti-endoglin antibody, TRC105. In March 2014, Santen licensed the global rights for the development of TRC105 in ophthalmology from Tracon. Under the terms of the agreement, the IND filing for DE-122 triggers a $3 million milestone payment to TRACON.

[DewDiligence]

TCON +36% on interim data from compassionate use trial:

http://finance.yahoo.com/news/tracon-pharmaceuticals-reports-ongoing-complete-110000602.html